Component

Clinical cure of cutaneous sporotrichosis

Study-specific endpoint; inspect claim context for model and measurement.

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. In 57 randomized patients, cure was 89.6% with once-daily versus 89.2% with three-times-daily SSKI.

    Experimental context and source evidence
    experimental_model
    Culture-confirmed cutaneous sporotrichosis; open-label schedule comparison.
    exposure_category
    Study-specific exposure, including pharmacological and in-vitro conditions; normal is the schema fallback outside the three availability categories.
    limitations
    Both groups received SSKI; no untreated comparator and no mechanism isolated.
    nutrient_topic
    Potassium iodide research collection; shared-anion and comparator studies are not all KI interventions. · Potassium iodide
    plain_language
    Clinical use against a skin fungal infection extends beyond the thyroid.
    primary_references
    Treatment of cutaneous sporotrichosis with one daily dose of potassium iodide. · 1996 · https://pubmed.ncbi.nlm.nih.gov/8866807/ · DOI 10.1097/00006454-199604000-00014

    Potassium iodide: thyroid and non-thyroid mechanisms, interactions and discovery questions (2026-09-18) · lines 432–438

    AI-assisted research curation; primary-study references, chemical references and label statements individually identified. Not publisher full text. · supports · Culture-confirmed cutaneous sporotrichosis; open-label schedule comparison. · source_derived_draft · unverified_draft

    ## ki-sporo-cure Clinical use against a skin fungal infection extends beyond the thyroid. In 57 randomized patients, cure was 89.6% with once-daily versus 89.2% with three-times-daily SSKI. Model: Culture-confirmed cutaneous sporotrichosis; open-label schedule comparison. Limitations: Both groups received SSKI; no untreated comparator and no mechanism isolated. Evidence location: Primary abstract Treatment of cutaneous sporotrichosis with one daily dose of potassium iodide. · 1996 · https://pubmed.ncbi.nlm.nih.gov/8866807/ · DOI 10.1097/00006454-199604000-00014
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards